Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Immunotherapy

Tumour Site

Presenters

Ioanna Eleftheriadou

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

I. Eleftheriadou1, S. Brett1, A. Domogala1, L. Patasic1, M.A. Kijewska1, K. Soor1, M. Georgouli1, J. Dopierala2, P. Fisher2, J. Jing3, J. Euesden4, K.R. Auger5, R. Roberts6, S. O'Sullivan1, L. Castelletti1, M. Damm1, D. Pankov7, L.A. Johnson8, A. Shalabi9, C. Britten1

Author affiliations

  • 1 Oncology Cell Therapy, GlaxoSmithKline GSK Stevenage - UK, SG1 2NY - Stevenage/GB
  • 2 Functional Genomics Computational Biology, GlaxoSmithKline, SG1 2NY - Stevenage/GB
  • 3 Computational Biology, GlaxoSmithKline, 19426 - Collegeville/US
  • 4 Research Statistics, GlaxoSmithKline, SG1 2NY - Stevenage/GB
  • 5 Immuno Oncology Combinations, GlaxoSmithKline, 19426 - Collegeville/US
  • 6 Cell And Gene Therapy Pds, GlaxoSmithKline, SG1 2NY - Stevenage/GB
  • 7 Oncology Cell Therapy, GlaxoSmithKline, 19426 - Collegeville/US
  • 8 Clinical Biomarkers Oncology Cell Therapy, GlaxoSmithKline, 19426 - Collegeville/US
  • 9 Clinical Development, Oncology, GlaxoSmithKline, 19426 - Collegeville/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3338

Background

Cell therapies have transformed the field of hematologic cancers, but treatment of solid tumours remains challenging. Emerging evidence suggests that T cell receptor (TCR)- engineered T cells targeting NY-ESO-1 hold promise for patients with solid tumours. NY-ESO-1 (CTAG1B) and LAGE1A (CTAG2) are tumour associated antigens (TAA) that share the SLLMWITQC peptide bound to human leukocyte antigen HLA-A*02 and are expressed in various cancers. GSK3377794 are autologous T cells engineered to express an affinity enhanced NY-ESO-1c259 TCR recognizing the SLLMWITQC/HLA-A*02 complex. Cell therapy trials using NY-ESO-1c259 TCR have shown promising efficacy in patients with synovial sarcoma, metastatic melanoma and multiple myeloma. Recently, a separate study using T cells targeted to NY-ESO-1 resulted in a partial response in a patient with advanced lung adenocarcinoma. This study aims to assess: 1) the prevalence of NY-ESO-1 and LAGE1A in various malignancies 2) GSK3377794 function against various tumours and 3) means to selectively modulate TAA expression in tumours to increase potential patient benefit.

Methods

Gene and transcript level RNAseq data for NY-ESO-1 and LAGE1A respectively, were extracted from TCGA B38 using ArrayStudio v10. A solid tumour biobank was established. HLA-A*02 expression was confirmed by flow cytometry and NY-ESO-1/LAGE1A levels were measured via qRT-PCR. Epigenetic modifiers were applied to increase TAA expression in tumours in vitro and in vivo. GSK3377794 anti-tumour function was determined by IFN-γ secretion.

Results

NY-ESO-1 and LAGE1A expression varied across malignancies and disease stages. Prevalence is high in synovial sarcoma and multiple myeloma (60-70%) and lower in lung cancer (12-15%). IFN-γ production by GSK3377794 positively correlates with antigen expression. Treatment with epigenetic modifiers lead to increased NY-ESO-1/LAGE1A expression in nonimmunogenic lung tumours, enhancing specific targeting by GSK3377794.

Conclusions

To date this is the most comprehensive analysis, using a set of clinically relevant sample specimens, that correlates antigen expression levels with functional responses of GSK3377794 in solid tumors. Epigenetic modifiers can improve GSK3377794 anti-tumour effect in lung cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GlaxoSmithKline.

Funding

GlaxoSmithKline.

Disclosure

I. Eleftheriadou: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. S. Brett: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. A. Domogala: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. L. Patasic: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. M.A. Kijewska: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. K. Soor: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. M. Georgouli: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. J. Dopierala: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. P. Fisher: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. J. Jing: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. J. Euesden: Full / Part-time employment: GlaxosmithKline. K.R. Auger: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. R. Roberts: Full / Part-time employment: GlaxosmithKline. S. O’Sullivan: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. L. Castelletti: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. M. Damm: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. D. Pankov: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. L.A. Johnson: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. A. Shalabi: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline. C. Britten: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxosmithKline.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.